Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

Patient enrollment complete for pivotal palonosetron trial

Oct. 5, 2001

VEGF receptor tyrosine kinase inhibitors and their use in cancer

Oct. 4, 2001

Pharmacological profile of PTK-787/ZK-222584, a new, orally active angiogenesis inhibitor

Oct. 4, 2001

Promising phase II results obtained for BBR-2778 in non-Hodgkin's lymphoma

Oct. 3, 2001

Protein kinase inhibitors reported by BASF team

Oct. 2, 2001

Naturally produced antitumor compounds identified by Aventis

Oct. 2, 2001

Orally active taxane derivatives under study at BMS

Oct. 1, 2001

Protein kinase inhibitors for cancer, cardiovascular disorders discovered at Vertex

Oct. 1, 2001

MMP inhibitor developed at Banyu induces apoptosis in human leukemia cells

Oct. 1, 2001

First NDA filing for PhotoCure in U.S.

Oct. 1, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for July 17, 2025.
Blenrep misstep? ODAC cites tox, GSK dosing neglect in MM
BioWorld
The rough ride presaged by briefing documents came to pass for GSK plc with the drug first approved by the U.S. FDA as Blenrep (belantamab mafodotin, bel-maf), as...
Atai Therapeutics discovers new 5-HT2A receptor partial agonists
BioWorld Science
Atai Therapeutics Inc. has synthesized new tetrahydro pyridine-substituted indole and azaindoles acting as 5-HT2A receptor partial agonists reported to be useful...
PHD inhibitors reported in Akebia Therapeutics patent
BioWorld Science
Akebia Therapeutics Inc. has identified new derivatives of ([1,2,4]triazolo[5,1-a]isoquinoline-5-carbonyl)glycinate acting as prolyl 4-hydroxylase (PHD) inhibitors.